Quick Overview of 10x Genomics

By Scott Lee • Monday, November 20 12:01 • Permanent Link

Shares of Biotechnology company 10x Genomics jumped 2.7% today. With many investors piling into TXG without a second thought, it may be a good idea to take a closer look at the stock. Here are some quick facts to get you started:

10x Genomics has moved 23.0% over the last year, and the S&P 500 logged a change of 16.0%
TXG has an average analyst rating of buy and is -21.01% away from its mean target price of $54.83 per share
Its trailing earnings per share (EPS) is $-1.92
10x Genomics has a trailing 12 month Price to Earnings (P/E) ratio of -22.6 while the S&P 500 average is 15.97
Its forward earnings per share (EPS) is $-1.49 and its forward P/E ratio is -29.1
The company has a Price to Book (P/B) ratio of 6.87 in contrast to the S&P 500's average ratio of 2.95
10x Genomics is part of the Industrials sector, which has an average P/E ratio of 20.49 and an average P/B of 3.78
The company has a free cash flow of $-46822000, which refers to the total sum of all its inflows and outflows of cash over the last quarter
10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium and chromium connect instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity on a cell-by-cell basis; single cell immune profiling for measuring the activity of immune cells and their targets; single cell Assay for Transposase Accessible Chromati (ATAC) for measuring epigenetics comprising the physical organization of DNA; and single cell multiome ATAC + gene expression for measuring the genetic activity and epigenetic programming in the same cells across tens of thousands of cells in a single experiment. The company also provides visium spatial gene expression solution for measuring spatial gene expression patterns across a single tissue sample or gene expression and protein co-detection when combined with immunofluorescence. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.